DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TOLTERODINE TARTRATE

Clinical Trials for Tolterodine Tartrate

Subscribe to access the full database, or Start Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00143377	Study to Determine The Effectiveness Of Detrusitol In Patients Diagnosed With OAB	Completed	Pfizer	Phase 4	2004-09-01	The purpose of this study is to evaluate the effectiveness of Detrusitol (tolterodine tartrate) SR, 4 mg once daily, on patient's perception of the symptoms of overactive bladder and which of these bothersome symptoms are improved with treatment.
NCT00293839	Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive Bladder	Completed	Alza Corporation, DE, USA	Phase 3	1969-12-31	The purpose of this study is to compare the efficacy of DITROPANÂ® XL (oxybutynin chloride) Extended-Release Tablets and DETROLÂ® LA (tolterodine tartrate extended-release capsules) in the reduction of urge urinary incontinence episodes during a 12-week treatment period in patients with overactive bladder. The secondary objective is to compare the tolerability of DITROPANÂ® XL (oxybutynin chloride) and DETROLÂ® LA (tolterodine tartrate) during a 12-week treatment period.
NCT00454740	Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder	Completed	Astellas Pharma Inc	Phase 3	2004-06-01	To evaluate the efficacy of 5 and10mg solifenacin succinate in patients with urgency who have OAB syndrome (urgency, with or without urge incontinence, usually with frequency and nocturia) and wish to switch from tolterodine tartrate extended release to solifenacin succinate due to lack of sufficient improvement in urgency episodes
NCT00768521	A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)	Completed	Merck Sharp & Dohme Corp.	Phase 1	2008-09-01	This study will design an alternative urodynamic platform to better evaluate treatment effects of medications for overactive bladder. Part II is dependent on results of Part I and may not be conducted.
NCT01089751	Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily	Completed	Allergan	Phase 4	2010-03-01	This study will investigate the safety and efficacy of Sanctura XR (trospium chloride) daily in reducing urgency, urinary frequency and urinary urge incontinence in female patients with incontinence refractory to Detrol LA (tolterodine tartrate extended release) 4 mg therapy.
NCT01175382	Combined Behavioral and Drug Treatment of Overactive Bladder in Men	Completed	University of Alabama at Birmingham	Phase 2/Phase 3	2010-07-01	The primary aim of this project is to evaluate the effectiveness of combined behavioral + drug therapy compared to behavioral treatment alone and drug therapy alone as a way to improve outcomes in the treatment of OAB symptoms in men. We hypothesize that combined therapy will result in better outcomes than either behavioral or drug therapy alone. The second aim is to compare two methods of implementing combined therapy: simultaneously as initial therapy vs. stepped therapy, in which therapies are combined following initial behavioral or drug therapy alone. The third aim is to examine the costs and cost-effectiveness of combined behavioral + drug therapy compared to behavioral or drug therapy alone.
NCT01512004	Propiverine Hydrochloride Extended-Release Capsule for Overactive Bladder	Completed	APOGEPHA Arzneimittel GmbH	Phase 3	2010-01-01	The purpose of this Phase III study is to evaluate the efficacy and safety of Propiverine Hydrochloride Extended-Release Capsule in the treatment of overactive bladder in Chinese population with urgent micturition, frequent micturition and/or urge urinary incontinence.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary